Cargando…

Anti-Tuberculosis Mur Inhibitors: Structural Insights and the Way Ahead for Development of Novel Agents

Mur enzymes serve as critical molecular devices for the synthesis of UDP-MurNAc-pentapeptide, the main building block of bacterial peptidoglycan polymer. These enzymes have been extensively studied for bacterial pathogens such as Escherichia coli and Staphylococcus aureus. Various selective and mixe...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Kunal, Khambete, Mihir, Abhyankar, Arundhati, Omri, Abdelwahab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058398/
https://www.ncbi.nlm.nih.gov/pubmed/36986477
http://dx.doi.org/10.3390/ph16030377
_version_ 1785016621703626752
author Mehta, Kunal
Khambete, Mihir
Abhyankar, Arundhati
Omri, Abdelwahab
author_facet Mehta, Kunal
Khambete, Mihir
Abhyankar, Arundhati
Omri, Abdelwahab
author_sort Mehta, Kunal
collection PubMed
description Mur enzymes serve as critical molecular devices for the synthesis of UDP-MurNAc-pentapeptide, the main building block of bacterial peptidoglycan polymer. These enzymes have been extensively studied for bacterial pathogens such as Escherichia coli and Staphylococcus aureus. Various selective and mixed Mur inhibitors have been designed and synthesized in the past few years. However, this class of enzymes remains relatively unexplored for Mycobacterium tuberculosis (Mtb), and thus offers a promising approach for drug design to overcome the challenges of battling this global pandemic. This review aims to explore the potential of Mur enzymes of Mtb by systematically scrutinizing the structural aspects of various reported bacterial inhibitors and implications concerning their activity. Diverse chemical scaffolds such as thiazolidinones, pyrazole, thiazole, etc., as well as natural compounds and repurposed compounds, have been reviewed to understand their in silico interactions with the receptor or their enzyme inhibition potential. The structural diversity and wide array of substituents indicate the scope of the research into developing varied analogs and providing valuable information for the purpose of modifying reported inhibitors of other multidrug-resistant microorganisms. Therefore, this provides an opportunity to expand the arsenal against Mtb and overcome multidrug-resistant tuberculosis.
format Online
Article
Text
id pubmed-10058398
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100583982023-03-30 Anti-Tuberculosis Mur Inhibitors: Structural Insights and the Way Ahead for Development of Novel Agents Mehta, Kunal Khambete, Mihir Abhyankar, Arundhati Omri, Abdelwahab Pharmaceuticals (Basel) Review Mur enzymes serve as critical molecular devices for the synthesis of UDP-MurNAc-pentapeptide, the main building block of bacterial peptidoglycan polymer. These enzymes have been extensively studied for bacterial pathogens such as Escherichia coli and Staphylococcus aureus. Various selective and mixed Mur inhibitors have been designed and synthesized in the past few years. However, this class of enzymes remains relatively unexplored for Mycobacterium tuberculosis (Mtb), and thus offers a promising approach for drug design to overcome the challenges of battling this global pandemic. This review aims to explore the potential of Mur enzymes of Mtb by systematically scrutinizing the structural aspects of various reported bacterial inhibitors and implications concerning their activity. Diverse chemical scaffolds such as thiazolidinones, pyrazole, thiazole, etc., as well as natural compounds and repurposed compounds, have been reviewed to understand their in silico interactions with the receptor or their enzyme inhibition potential. The structural diversity and wide array of substituents indicate the scope of the research into developing varied analogs and providing valuable information for the purpose of modifying reported inhibitors of other multidrug-resistant microorganisms. Therefore, this provides an opportunity to expand the arsenal against Mtb and overcome multidrug-resistant tuberculosis. MDPI 2023-03-01 /pmc/articles/PMC10058398/ /pubmed/36986477 http://dx.doi.org/10.3390/ph16030377 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mehta, Kunal
Khambete, Mihir
Abhyankar, Arundhati
Omri, Abdelwahab
Anti-Tuberculosis Mur Inhibitors: Structural Insights and the Way Ahead for Development of Novel Agents
title Anti-Tuberculosis Mur Inhibitors: Structural Insights and the Way Ahead for Development of Novel Agents
title_full Anti-Tuberculosis Mur Inhibitors: Structural Insights and the Way Ahead for Development of Novel Agents
title_fullStr Anti-Tuberculosis Mur Inhibitors: Structural Insights and the Way Ahead for Development of Novel Agents
title_full_unstemmed Anti-Tuberculosis Mur Inhibitors: Structural Insights and the Way Ahead for Development of Novel Agents
title_short Anti-Tuberculosis Mur Inhibitors: Structural Insights and the Way Ahead for Development of Novel Agents
title_sort anti-tuberculosis mur inhibitors: structural insights and the way ahead for development of novel agents
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058398/
https://www.ncbi.nlm.nih.gov/pubmed/36986477
http://dx.doi.org/10.3390/ph16030377
work_keys_str_mv AT mehtakunal antituberculosismurinhibitorsstructuralinsightsandthewayaheadfordevelopmentofnovelagents
AT khambetemihir antituberculosismurinhibitorsstructuralinsightsandthewayaheadfordevelopmentofnovelagents
AT abhyankararundhati antituberculosismurinhibitorsstructuralinsightsandthewayaheadfordevelopmentofnovelagents
AT omriabdelwahab antituberculosismurinhibitorsstructuralinsightsandthewayaheadfordevelopmentofnovelagents